China NMPA

Boehringer Ingelheim HERNEXEOS Approved as First Oral HER2 NSCLC Therapy

Ingelheim, Germany – May 22, 2026 Boehringer Ingelheim announced that China’s National Medical Products Administration (NMPA) has conditionally approved...

By cGxPwire Editor
May 23, 2026

Pharma

HUTCHMED’s Savolitinib NDA Gains Priority Review in China

Hong Kong / Shanghai | December 30, 2025 — HUTCHMED announced that China’s drug regulator has accepted the New...

By cGxPwire Editor
December 30, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

China NMPA

Boehringer Ingelheim HERNEXEOS Approved as First Oral HER2 NSCLC Therapy

HUTCHMED’s Savolitinib NDA Gains Priority Review in China